Show simple item record

dc.contributor.authorWischik, Claude M
dc.contributor.authorWischik, Damon J
dc.contributor.authorStorey, John M D
dc.contributor.authorHarrington, Charles R
dc.contributor.editorMartinez, Ana
dc.date.accessioned2014-12-03T11:01:01Z
dc.date.available2014-12-03T11:01:01Z
dc.date.issued2010
dc.identifier.citationWischik , C M , Wischik , D J , Storey , J M D & Harrington , C R 2010 , Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies . in A Martinez (ed.) , Emerging drugs and targets for Alzheimer's disease : Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism . vol. 1 , RSC Drug Discovery Series , Cambridge , pp. 210-232 . https://doi.org/10.1039/9781849731065en
dc.identifier.isbn978-1-84973-106-5
dc.identifier.otherPURE: 14419807
dc.identifier.otherPURE UUID: 001dbfca-e6eb-420d-a7b6-8e674faba32b
dc.identifier.otherORCID: /0000-0002-5261-5467/work/73579127
dc.identifier.urihttp://hdl.handle.net/2164/4066
dc.format.extent23
dc.language.isoeng
dc.relation.ispartofEmerging drugs and targets for Alzheimer's diseaseen
dc.relation.ispartofseriesRSC Drug Discovery Seriesen
dc.rightsUncorrected proof - Publishers have granted rights to make available on internet.en
dc.subjectRM Therapeutics. Pharmacologyen
dc.subject.lccRMen
dc.titleRationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathiesen
dc.typeBook itemen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Chemistryen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.description.versionPreprinten
dc.identifier.doihttps://doi.org/10.1039/9781849731065


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record